Another win for natural immunity: Heba N. Altarawneh "Effect of prior infection, vaccination, and hybrid immunity against symptomatic BA.1 and BA.2 Omicron infections and severe COVID-19 in Qatar"
by Paul Alexander
Key statement: Effect of prior infection, vaccination, and hybrid immunity against symptomatic BA.1 and BA.2 Omicron infections and severe COVID-19 in Qatar
“There are no discernable differences in the effects of prior infection, vaccination, and hybrid immunity against BA.1 versus BA.2.”
This is the key statement and the issue is if you boosted and got a surge in vaccinal antibodies, what is the impact on immunity and severity and mortality? Vaccinal Abs quickly wane. The data is clear on that. Moreover there is now NEJM evidence showing no difference between 3rd and 4th (2nd booster). I consider NEJM a medical journal rag and corrupted journal, go ask its senior editor who stated in FDA meeting that children needed to take the safety untested vaccine first so as to assess the safety. Imagine that. Smoke that for a bit.
We are seeing the data that shows that the 3rd booster is devastating (UK data) and especially for those 50 years and over as to hospitalization and death.
Qatar researchers investigated SARS-CoV-2 Omicron symptomatic BA.1 infection, symptomatic BA.2 infection, BA.1 hospitalization and death, and BA.2 hospitalization and death, between December 23, 2021 and February 21, 2022. The researchers conducted 6 national, matched, test-negative case-control studies were conducted to examine effectiveness of BNT162b2 (Pfizer-BioNTech) vaccine, mRNA-1273 (Moderna) vaccine, natural immunity due to prior infection with pre-Omicron variants, and hybrid immunity from prior infection and vaccination.
“Effectiveness of only prior infection against symptomatic BA.2 infection was 46.1% (95% CI: 39.5-51.9%). Effectiveness of only two-dose BNT162b2 vaccination was negligible at -1.1% (95% CI: -7.1-4.6), but nearly all individuals had received their second dose several months earlier. Effectiveness of only three-dose BNT162b2 vaccination was 52.2% (95% CI: 48.1-55.9%). Effectiveness of hybrid immunity of prior infection and two-dose BNT162b2 vaccination was 55.1% (95% CI: 50.9-58.9%).”
Qatar source, pre-print: